Artificial Intelligence technologies for assessing skin lesions selected for referral on the urgent suspected cancer pathway to detect benign lesions and reduce secondary care specialist appointmentsStatus:In developmentProgramme:Diagnostics guidanceExpected publication date: TBC
Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer (IPG784)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 2 April 2024
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people aged 12 and over [ID6189]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (TA950)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 February 2024
Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tislelizumab for previously treated advanced oesophageal squamous cell cancer [ID4070]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Toripalimab with chemotherapy for treating advanced oesophageal squamous cell cancer without previous systemic chemotherapy ID6414Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC